Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tubulin and microtubule-associated proteins (MAPs) constitute the primary structural components of the cellular cytoskeleton, essential for maintaining cell architecture, facilitating intracellular transport, and orchestrating chromosome segregation during mitosis [1, 2]. Tubulin exists as alpha and beta heterodimers that polymerize into dynamic microtubules, while MAPs regulate their stability, assembly, and interaction with other cellular components [2]. The nuclear matrix serves as a proteinaceous scaffold within the nucleus, providing structural support for chromatin organization and DNA-related processes [3]. In clinical oncology, tubulin is a cornerstone therapeutic target; microtubule-targeting agents (MTAs) such as taxanes and vinca alkaloids disrupt spindle dynamics, leading to cell cycle arrest at the metaphase-anaphase transition and subsequent apoptosis [4]. Beyond cancer, MAPs like Tau are critical targets in neurodegenerative research due to their role in stabilizing axonal microtubules and their pathological aggregation in tauopathies [5]. The nuclear matrix also contains proteins involved in genomic stability that are targeted by specific chemotherapeutic agents to disrupt cancer cell proliferation [3].
Microtubule-targeting agents (MTAs) act by binding to specific sites on tubulin dimers to either stabilize microtubules against depolymerization (e.g., taxanes, epothilones) or inhibit their polymerization (e.g., vinca alkaloids, eribulin), both of which disrupt the mitotic spindle and trigger cell cycle arrest and apoptosis [4, 5].
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tubulin and microtubule-associated proteins (MAPs) (Tubulin/MAPs).